First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827

Source: Clinical Genitourinary Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Jian Zhang Dongmei Ji Li Cai Herui Yao Min Yan Xiaojia Wang Weina Shen Yiqun Du Hui Pang Xiuping Lai Huiai Zeng Jian Huang Yan Sun Xinxin Peng Junfang Xu Jing Yang Fei Yang Ting Xu Xichun Hu Source Type: research